GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » Shiller PE Ratio

AnaptysBio (AnaptysBio) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AnaptysBio Shiller PE Ratio Historical Data

The historical data trend for AnaptysBio's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Shiller PE Ratio Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AnaptysBio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AnaptysBio's Shiller PE Ratio

For the Biotechnology subindustry, AnaptysBio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Shiller PE Ratio falls into.



AnaptysBio Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AnaptysBio's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, AnaptysBio's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.64/131.7762*131.7762
=-1.640

Current CPI (Mar. 2024) = 131.7762.

AnaptysBio Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 100.560 0.000
201409 0.011 100.428 0.014
201412 -0.004 99.070 -0.005
201503 -0.004 99.621 -0.005
201506 -0.001 100.684 -0.001
201509 -0.103 100.392 -0.135
201512 -0.248 99.792 -0.327
201603 -0.063 100.470 -0.083
201606 0.012 101.688 0.016
201609 -0.079 101.861 -0.102
201612 -0.235 101.863 -0.304
201703 -0.750 102.862 -0.961
201706 -0.130 103.349 -0.166
201709 -0.450 104.136 -0.569
201712 -0.300 104.011 -0.380
201803 -0.630 105.290 -0.788
201806 -0.570 106.317 -0.706
201809 -0.660 106.507 -0.817
201812 -0.640 105.998 -0.796
201903 -0.820 107.251 -1.008
201906 -0.890 108.070 -1.085
201909 -1.150 108.329 -1.399
201912 -0.750 108.420 -0.912
202003 -0.300 108.902 -0.363
202006 -0.790 108.767 -0.957
202009 -0.870 109.815 -1.044
202012 1.230 109.897 1.475
202103 -0.660 111.754 -0.778
202106 -0.020 114.631 -0.023
202109 -0.240 115.734 -0.273
202112 -1.180 117.630 -1.322
202203 -1.310 121.301 -1.423
202206 -1.150 125.017 -1.212
202209 -1.180 125.227 -1.242
202212 -0.930 125.222 -0.979
202303 -1.580 127.348 -1.635
202306 -1.500 128.729 -1.536
202309 -1.410 129.860 -1.431
202312 -1.590 129.419 -1.619
202403 -1.640 131.776 -1.640

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AnaptysBio  (NAS:ANAB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AnaptysBio Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio (AnaptysBio) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.
Executives
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau officer: General Counsel C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Daniel Faga director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Dennis Mulroy officer: Chief Financial Officer
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hamza Suria director, officer: President, CEO C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware director C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei officer: Chief Medical Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
James N Topper director 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301